Titre : Metalloproteases

Metalloproteases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Metalloproteases : Questions médicales les plus fréquentes", "headline": "Metalloproteases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Metalloproteases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-14", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Metalloproteases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Peptide hydrolases", "url": "https://questionsmedicales.fr/mesh/D010447", "about": { "@type": "MedicalCondition", "name": "Peptide hydrolases", "code": { "@type": "MedicalCode", "code": "D010447", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Metalloendopeptidases", "alternateName": "Metalloendopeptidases", "url": "https://questionsmedicales.fr/mesh/D008666", "about": { "@type": "MedicalCondition", "name": "Metalloendopeptidases", "code": { "@type": "MedicalCode", "code": "D008666", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Collagenases", "alternateName": "Collagenases", "url": "https://questionsmedicales.fr/mesh/D017364", "about": { "@type": "MedicalCondition", "name": "Collagenases", "code": { "@type": "MedicalCode", "code": "D017364", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.205" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Microbial collagenase", "alternateName": "Microbial Collagenase", "url": "https://questionsmedicales.fr/mesh/D003012", "about": { "@type": "MedicalCondition", "name": "Microbial collagenase", "code": { "@type": "MedicalCode", "code": "D003012", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.205.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Microbial collagenase", "alternateName": "Microbial Collagenase", "url": "https://questionsmedicales.fr/mesh/D003012", "about": { "@type": "MedicalCondition", "name": "Microbial collagenase", "code": { "@type": "MedicalCode", "code": "D003012", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.205.500" } } }, { "@type": "MedicalWebPage", "name": "Enzymes de conversion de l'endothéline", "alternateName": "Endothelin-Converting Enzymes", "url": "https://questionsmedicales.fr/mesh/D000072396", "about": { "@type": "MedicalCondition", "name": "Enzymes de conversion de l'endothéline", "code": { "@type": "MedicalCode", "code": "D000072396", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.229" } } }, { "@type": "MedicalWebPage", "name": "Gelatinases", "alternateName": "Gelatinases", "url": "https://questionsmedicales.fr/mesh/D018093", "about": { "@type": "MedicalCondition", "name": "Gelatinases", "code": { "@type": "MedicalCode", "code": "D018093", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.252" } } }, { "@type": "MedicalWebPage", "name": "Insulinase", "alternateName": "Insulysin", "url": "https://questionsmedicales.fr/mesh/D007339", "about": { "@type": "MedicalCondition", "name": "Insulinase", "code": { "@type": "MedicalCode", "code": "D007339", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.300" } } }, { "@type": "MedicalWebPage", "name": "Lysostaphin", "alternateName": "Lysostaphin", "url": "https://questionsmedicales.fr/mesh/D008248", "about": { "@type": "MedicalCondition", "name": "Lysostaphin", "code": { "@type": "MedicalCode", "code": "D008248", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.452" } } }, { "@type": "MedicalWebPage", "name": "Matrix metalloproteinases", "alternateName": "Matrix Metalloproteinases", "url": "https://questionsmedicales.fr/mesh/D020782", "about": { "@type": "MedicalCondition", "name": "Matrix metalloproteinases", "code": { "@type": "MedicalCode", "code": "D020782", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.525" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Matrix metalloproteinase 14", "alternateName": "Matrix Metalloproteinase 14", "url": "https://questionsmedicales.fr/mesh/D053511", "about": { "@type": "MedicalCondition", "name": "Matrix metalloproteinase 14", "code": { "@type": "MedicalCode", "code": "D053511", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.525.300.500" } } }, { "@type": "MedicalWebPage", "name": "Matrix metalloproteinase 15", "alternateName": "Matrix Metalloproteinase 15", "url": "https://questionsmedicales.fr/mesh/D053517", "about": { "@type": "MedicalCondition", "name": "Matrix metalloproteinase 15", "code": { "@type": "MedicalCode", "code": "D053517", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.525.300.625" } } }, { "@type": "MedicalWebPage", "name": "Matrix metalloproteinase 16", "alternateName": "Matrix Metalloproteinase 16", "url": "https://questionsmedicales.fr/mesh/D053513", "about": { "@type": "MedicalCondition", "name": "Matrix metalloproteinase 16", "code": { "@type": "MedicalCode", "code": "D053513", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.525.300.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Matrix metalloproteinase 14", "alternateName": "Matrix Metalloproteinase 14", "url": "https://questionsmedicales.fr/mesh/D053511", "about": { "@type": "MedicalCondition", "name": "Matrix metalloproteinase 14", "code": { "@type": "MedicalCode", "code": "D053511", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.525.300.500" } } }, { "@type": "MedicalWebPage", "name": "Matrix metalloproteinase 15", "alternateName": "Matrix Metalloproteinase 15", "url": "https://questionsmedicales.fr/mesh/D053517", "about": { "@type": "MedicalCondition", "name": "Matrix metalloproteinase 15", "code": { "@type": "MedicalCode", "code": "D053517", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.525.300.625" } } }, { "@type": "MedicalWebPage", "name": "Matrix metalloproteinase 16", "alternateName": "Matrix Metalloproteinase 16", "url": "https://questionsmedicales.fr/mesh/D053513", "about": { "@type": "MedicalCondition", "name": "Matrix metalloproteinase 16", "code": { "@type": "MedicalCode", "code": "D053513", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.525.300.750" } } }, { "@type": "MedicalWebPage", "name": "Procollagen peptidase", "alternateName": "Procollagen N-Endopeptidase", "url": "https://questionsmedicales.fr/mesh/D011348", "about": { "@type": "MedicalCondition", "name": "Procollagen peptidase", "code": { "@type": "MedicalCode", "code": "D011348", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.664" } } }, { "@type": "MedicalWebPage", "name": "Bacillus thermoproteolyticus neutral proteinase", "alternateName": "Thermolysin", "url": "https://questionsmedicales.fr/mesh/D013820", "about": { "@type": "MedicalCondition", "name": "Bacillus thermoproteolyticus neutral proteinase", "code": { "@type": "MedicalCode", "code": "D013820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.374.827" } } } ] }, { "@type": "MedicalWebPage", "name": "Metalloexopeptidases", "alternateName": "Metalloexopeptidases", "url": "https://questionsmedicales.fr/mesh/D045727", "about": { "@type": "MedicalCondition", "name": "Metalloexopeptidases", "code": { "@type": "MedicalCode", "code": "D045727", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.555" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Carboxypeptidases A", "alternateName": "Carboxypeptidases A", "url": "https://questionsmedicales.fr/mesh/D043422", "about": { "@type": "MedicalCondition", "name": "Carboxypeptidases A", "code": { "@type": "MedicalCode", "code": "D043422", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.555.350" } } }, { "@type": "MedicalWebPage", "name": "Cystinyl aminopeptidase", "alternateName": "Cystinyl Aminopeptidase", "url": "https://questionsmedicales.fr/mesh/D010122", "about": { "@type": "MedicalCondition", "name": "Cystinyl aminopeptidase", "code": { "@type": "MedicalCode", "code": "D010122", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.555.400" } } }, { "@type": "MedicalWebPage", "name": "Glutamate carboxypeptidase II", "alternateName": "Glutamate Carboxypeptidase II", "url": "https://questionsmedicales.fr/mesh/D043425", "about": { "@type": "MedicalCondition", "name": "Glutamate carboxypeptidase II", "code": { "@type": "MedicalCode", "code": "D043425", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.555.500" } } }, { "@type": "MedicalWebPage", "name": "Glutamyl aminopeptidase", "alternateName": "Glutamyl Aminopeptidase", "url": "https://questionsmedicales.fr/mesh/D043384", "about": { "@type": "MedicalCondition", "name": "Glutamyl aminopeptidase", "code": { "@type": "MedicalCode", "code": "D043384", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.555.600" } } }, { "@type": "MedicalWebPage", "name": "Leucyl Aminopeptidase", "alternateName": "Leucyl Aminopeptidase", "url": "https://questionsmedicales.fr/mesh/D007931", "about": { "@type": "MedicalCondition", "name": "Leucyl Aminopeptidase", "code": { "@type": "MedicalCode", "code": "D007931", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.555.700" } } }, { "@type": "MedicalWebPage", "name": "Lysine carboxypeptidase", "alternateName": "Lysine Carboxypeptidase", "url": "https://questionsmedicales.fr/mesh/D001121", "about": { "@type": "MedicalCondition", "name": "Lysine carboxypeptidase", "code": { "@type": "MedicalCode", "code": "D001121", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.656.675.555.750" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Metalloproteases", "alternateName": "Metalloproteases", "code": { "@type": "MedicalCode", "code": "D045726", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Tania Fontanil", "url": "https://questionsmedicales.fr/author/Tania%20Fontanil", "affiliation": { "@type": "Organization", "name": "Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, 33006 Oviedo, Spain." } }, { "@type": "Person", "name": "Yamina Mohamedi", "url": "https://questionsmedicales.fr/author/Yamina%20Mohamedi", "affiliation": { "@type": "Organization", "name": "Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, 33006 Oviedo, Spain." } }, { "@type": "Person", "name": "Teresa Cobo", "url": "https://questionsmedicales.fr/author/Teresa%20Cobo", "affiliation": { "@type": "Organization", "name": "Departamento de Cirugía y Especialidades Médico-Quirúrgicas, Universidad de Oviedo, 33006 Oviedo, Spain." } }, { "@type": "Person", "name": "Santiago Cal", "url": "https://questionsmedicales.fr/author/Santiago%20Cal", "affiliation": { "@type": "Organization", "name": "Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, 33006 Oviedo, Spain." } }, { "@type": "Person", "name": "Álvaro J Obaya", "url": "https://questionsmedicales.fr/author/%C3%81lvaro%20J%20Obaya", "affiliation": { "@type": "Organization", "name": "Departamento de Biología Funcional, Área de Fisiología, Universidad de Oviedo, 33006 Oviedo, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE).", "datePublished": "2023-01-25", "url": "https://questionsmedicales.fr/article/36830873", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/biomedicines11020336" } }, { "@type": "ScholarlyArticle", "name": "Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.", "datePublished": "2022-12-18", "url": "https://questionsmedicales.fr/article/36624015", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clml.2022.12.008" } }, { "@type": "ScholarlyArticle", "name": "Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies.", "datePublished": "2022-12-01", "url": "https://questionsmedicales.fr/article/36632576", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.14740/jh1042" } }, { "@type": "ScholarlyArticle", "name": "A Prediction Model Based on the Risk Factors Associated with Pathological Upgrading in Patients with Early-Stage Gastric Neoplasms Diagnosed by Endoscopic Forceps Biopsy.", "datePublished": "2022-09-02", "url": "https://questionsmedicales.fr/article/36052614", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5009/gnl220060" } }, { "@type": "ScholarlyArticle", "name": "Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database.", "datePublished": "2022-05-12", "url": "https://questionsmedicales.fr/article/35720036", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/3689895" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Hydrolases", "item": "https://questionsmedicales.fr/mesh/D006867" }, { "@type": "ListItem", "position": 5, "name": "Peptide hydrolases", "item": "https://questionsmedicales.fr/mesh/D010447" }, { "@type": "ListItem", "position": 6, "name": "Metalloproteases", "item": "https://questionsmedicales.fr/mesh/D045726" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Metalloproteases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Metalloproteases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Metalloproteases", "description": "Comment diagnostiquer une dysfonction des métalloprotéases ?\nQuels marqueurs sont utilisés pour le diagnostic ?\nLes imageries sont-elles utiles pour le diagnostic ?\nQuels tests génétiques sont disponibles ?\nComment évaluer l'activité enzymatique ?", "url": "https://questionsmedicales.fr/mesh/D045726?mesh_terms=Prostatic+Neoplasms&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Metalloproteases", "description": "Quels symptômes indiquent une surproduction de métalloprotéases ?\nLes symptômes varient-ils selon le type de métalloprotéases ?\nQuels signes cliniques sont associés à une déficience ?\nLes symptômes sont-ils toujours visibles ?\nComment les symptômes évoluent-ils avec l'âge ?", "url": "https://questionsmedicales.fr/mesh/D045726?mesh_terms=Prostatic+Neoplasms&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Metalloproteases", "description": "Comment prévenir les maladies liées aux métalloprotéases ?\nLes suppléments nutritionnels sont-ils utiles ?\nL'évitement de certains aliments est-il recommandé ?\nLe contrôle du stress est-il important ?\nLes examens réguliers sont-ils nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D045726?mesh_terms=Prostatic+Neoplasms&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Metalloproteases", "description": "Quels traitements ciblent les métalloprotéases ?\nLes thérapies géniques sont-elles une option ?\nComment les anti-inflammatoires aident-ils ?\nLes traitements sont-ils personnalisés ?\nQuels sont les effets secondaires des inhibiteurs ?", "url": "https://questionsmedicales.fr/mesh/D045726?mesh_terms=Prostatic+Neoplasms&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Metalloproteases", "description": "Quelles complications peuvent survenir avec une suractivité ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles prévisibles ?\nQuelles sont les complications liées à une déficience ?", "url": "https://questionsmedicales.fr/mesh/D045726?mesh_terms=Prostatic+Neoplasms&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Metalloproteases", "description": "Quels facteurs augmentent le risque de dysfonction ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe tabagisme est-il un facteur de risque ?\nLe stress chronique influence-t-il le risque ?\nL'exposition à des toxines est-elle un facteur ?", "url": "https://questionsmedicales.fr/mesh/D045726?mesh_terms=Prostatic+Neoplasms&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des métalloprotéases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies tissulaires peuvent évaluer l'activité des métalloprotéases." } }, { "@type": "Question", "name": "Quels marqueurs sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de métalloprotéases dans le sérum ou les tissus peuvent servir de marqueurs diagnostiques." } }, { "@type": "Question", "name": "Les imageries sont-elles utiles pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'imagerie peut aider à visualiser les tissus affectés par des déséquilibres enzymatiques." } }, { "@type": "Question", "name": "Quels tests génétiques sont disponibles ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent identifier des mutations affectant la production de métalloprotéases." } }, { "@type": "Question", "name": "Comment évaluer l'activité enzymatique ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques spécifiques mesurent l'activité des métalloprotéases dans les échantillons." } }, { "@type": "Question", "name": "Quels symptômes indiquent une surproduction de métalloprotéases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une inflammation, des douleurs articulaires et des lésions tissulaires peuvent survenir." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de métalloprotéases ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, différents types de métalloprotéases peuvent causer des symptômes variés selon les tissus affectés." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à une déficience ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Une cicatrisation lente et des anomalies dans la matrice extracellulaire peuvent être observées." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours visibles ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Non, certaines dysfonctions peuvent être asymptomatiques jusqu'à des stades avancés." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "L'activité des métalloprotéases peut augmenter avec l'âge, aggravant les symptômes dégénératifs." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux métalloprotéases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut aider." } }, { "@type": "Question", "name": "Les suppléments nutritionnels sont-ils utiles ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Certains suppléments, comme les antioxydants, peuvent soutenir la fonction des métalloprotéases." } }, { "@type": "Question", "name": "L'évitement de certains aliments est-il recommandé ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, réduire les aliments pro-inflammatoires peut aider à réguler l'activité des métalloprotéases." } }, { "@type": "Question", "name": "Le contrôle du stress est-il important ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut influencer l'activité des métalloprotéases, donc sa gestion est cruciale." } }, { "@type": "Question", "name": "Les examens réguliers sont-ils nécessaires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des examens réguliers peuvent aider à détecter précocement des déséquilibres enzymatiques." } }, { "@type": "Question", "name": "Quels traitements ciblent les métalloprotéases ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques des métalloprotéases sont utilisés pour traiter certaines maladies." } }, { "@type": "Question", "name": "Les thérapies géniques sont-elles une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie génique peut corriger des mutations affectant la production de métalloprotéases." } }, { "@type": "Question", "name": "Comment les anti-inflammatoires aident-ils ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent réduire l'inflammation causée par une suractivité des métalloprotéases." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction du type de métalloprotéases impliqué." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des inhibiteurs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les inhibiteurs peuvent causer des effets secondaires comme des troubles gastro-intestinaux." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une suractivité ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies dégénératives, comme l'arthrite, peuvent résulter d'une suractivité des métalloprotéases." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent entraîner des douleurs chroniques et une mobilité réduite, affectant la qualité de vie." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être prévisibles en surveillant les niveaux d'activité enzymatique." } }, { "@type": "Question", "name": "Quelles sont les complications liées à une déficience ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une cicatrisation lente et des infections peuvent survenir en raison d'une déficience en métalloprotéases." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de dysfonction ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, le mode de vie sédentaire et une alimentation déséquilibrée augmentent le risque." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies liées aux métalloprotéases peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut exacerber l'activité des métalloprotéases et augmenter les maladies associées." } }, { "@type": "Question", "name": "Le stress chronique influence-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber l'équilibre des métalloprotéases, augmentant le risque de maladies." } }, { "@type": "Question", "name": "L'exposition à des toxines est-elle un facteur ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certaines toxines environnementales peut affecter l'activité des métalloprotéases." } } ] } ] }

Sous-catégories

20 au total
└─

Metalloendopeptidases

Metalloendopeptidases D008666 - D08.811.277.656.675.374
└─

Metalloexopeptidases

Metalloexopeptidases D045727 - D08.811.277.656.675.555
└─└─

Collagenases

Collagenases D017364 - D08.811.277.656.675.374.205
└─└─

Enzymes de conversion de l'endothéline

Endothelin-Converting Enzymes D000072396 - D08.811.277.656.675.374.229
└─└─

Gelatinases

Gelatinases D018093 - D08.811.277.656.675.374.252
└─└─

Insulinase

Insulysin D007339 - D08.811.277.656.675.374.300
└─└─

Lysostaphin

Lysostaphin D008248 - D08.811.277.656.675.374.452
└─└─

Matrix metalloproteinases

Matrix Metalloproteinases D020782 - D08.811.277.656.675.374.525
└─└─

Procollagen peptidase

Procollagen N-Endopeptidase D011348 - D08.811.277.656.675.374.664
└─└─

Bacillus thermoproteolyticus neutral proteinase

Thermolysin D013820 - D08.811.277.656.675.374.827
└─└─

Carboxypeptidases A

Carboxypeptidases A D043422 - D08.811.277.656.675.555.350
└─└─

Cystinyl aminopeptidase

Cystinyl Aminopeptidase D010122 - D08.811.277.656.675.555.400
└─└─

Glutamate carboxypeptidase II

Glutamate Carboxypeptidase II D043425 - D08.811.277.656.675.555.500
└─└─

Glutamyl aminopeptidase

Glutamyl Aminopeptidase D043384 - D08.811.277.656.675.555.600
└─└─

Leucyl Aminopeptidase

Leucyl Aminopeptidase D007931 - D08.811.277.656.675.555.700
└─└─

Lysine carboxypeptidase

Lysine Carboxypeptidase D001121 - D08.811.277.656.675.555.750
└─└─└─

Microbial collagenase

Microbial Collagenase D003012 - D08.811.277.656.675.374.205.500
└─└─└─└─

Matrix metalloproteinase 14

Matrix Metalloproteinase 14 D053511 - D08.811.277.656.675.374.525.300.500
└─└─└─└─

Matrix metalloproteinase 15

Matrix Metalloproteinase 15 D053517 - D08.811.277.656.675.374.525.300.625
└─└─└─└─

Matrix metalloproteinase 16

Matrix Metalloproteinase 16 D053513 - D08.811.277.656.675.374.525.300.750

Sources (10000 au total)

Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusion (MLN-TK) is an entity encompassed of a heterogeneous group of rare hematopoietic neoplasms that are driven by gene fusion i... The retrospective study included patients with confirmed MLN-TK from 3 centers and assessed demographic and clinical variables, treatment, and outcomes.... Forty-two patients with confirmed MLN-TK [PDGFRA (n = 22), PDGFRB (n = 4), FGFR1(n = 10), JAK2 (n = 2); and FLT3 (n = 3)] were included. Fifteen of 25 (60%) chronic-phased patients received upfront TK... The outcomes of upfront TKI therapy are excellent for MLN-TK in both chronic and blast phases, regardless of gene abnormalities....

A Prediction Model Based on the Risk Factors Associated with Pathological Upgrading in Patients with Early-Stage Gastric Neoplasms Diagnosed by Endoscopic Forceps Biopsy.

The discrepancies between the diagnosis of preoperative endoscopic forceps biopsy (EFB) and endoscopic submucosal dissection (ESD) in patients with early gastric neoplasm (EGN) exist objectively. Amon... We retrospectively collected the records of 978 patients who underwent ESD from December 1, 2017 to July 31, 2021 and who had a final histopathology determination of EGN. A nomogram to predict the ris... The ratio of pathological upgrading was 510 of 953 (53.5%). Clinical, laboratorial and endoscopic characteristics were analyzed using univariable and binary multivariable logistic regression analyses.... The clinical value of identifying the preoperative diagnosis of EGN lesions is limited when using EFB separately. We have developed a nomogram that can predict the probability of pathological upgradin...

Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database.

The incidence of nonfunctional pancreatic neuroendocrine neoplasms (NF-pNENs) has been increasing annually. This study is aimed at investigating the clinicopathological characteristics and high-risk f... pNEN patients in this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. This study analyzed patients diagnosed with NF-pNENs from 2000 to 2017 who met the inclu... From 2000 to 2017, the SEER database registered 10576 patients with pNENs and 1774 patients with liver metastases. Cox analysis revealed that age, sex, primary site, grade, tumor stage, surgery, tumor... The incidence of pNENs has been increasing annually, and the liver has been the most common site of metastasis. Liver metastasis in patients with NF-pNENs, related to tumor size and grade, affected th...

Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database.

The depth of the prostate-specific antigen (PSA) decline after androgen receptor pathway inhibitor (ARPI) treatment combined with androgen deprivation therapy for patients with metastatic hormone-sens... We conducted a retrospective multicenter study of patients with mHSPC treated with apalutamide from May 2018 to September 2023 registered in the Real-World Evidence APA registry across 20 centers.... We included 633 patients with mHSPC. The median age at diagnosis was 68 yr (interquartile range [IQR] 63-75) and median PSA was 16 ng/ml (IQR 7.5-64). Some 63% of the short had low-volume disease, 51%... Patients with a complete PSA response after 3 mo of apalutamide treatment face a very low risk of progression within 2 yr. Conversely, nearly 50% of patients with an incomplete PSA response will exper... For patients with metastatic prostate cancer that is still responsive to hormone therapy, a complete response after treatment with a drug called apalutamide is associated with a very low risk of progr...

Prevalence of clinically significant prostate carcinoma in Prostate Imaging Reporting and Data System (PIRADS) 3 lesions detected in the peripheral zone on biparametric magnetic resonance imaging (MRI)-a local experience.

The aim of this study was to determine whether biparametric magnetic resonance imaging (MRI) is effective in the diagnosis of clinically significant prostate cancer in prostate peripheral zone Prostat... Patients who underwent biparametric MRI over a 12-month period from January 2022 to December 2022 and were diagnosed with PIRADS 3 lesion in the peripheral zone were included in the study. No patient ... Sixty-one out of 688 MRIs (8.8%) performed over the study period had a PIRADS 3 lesion in the peripheral zone where contrast is supposed to add value. Fifty-eight of the 61 went ahead to biopsy, and c... Biparametric MRI without contrast offers a reliable alternative to multiparametric MRI with minimum or neglible impact on clinically significant prostate cancer (csPCa) diagnosis in peripheral zone PI...

Malignant Epithelioid Mesenchymal Neoplasm with FUS::CREM Gene Fusion Arising in the Tongue: A Case Report Detailing Clinicopathological, Imaging, and Molecular Features.

FUS::CREM fusion is a distinct primary driver in rare neoplasms of the head and neck and other anatomic sites. Herein, we describe the clinicopathological, imaging, and molecular features of a maligna...

Epidemiology, Pattern, and Survival of Multiple Primary Malignant Neoplasms in Southeast Iran: Results of Kerman Population-Based Cancer Registry 2014-2020.

Cancer survivors may experience a subsequent primary cancer that affects their survival and quality of life. This study aimed to investigate the epidemiology of multiple primary malignant neoplasms (M... In this retrospective cohort study, all patients who had been diagnosed with primary cancers and registered with the Kerman Cancer Registry Program (KPBCR) during 2014-2020 were included. MPMNs were d... Of 26,315 patients registered with a primary cancer diagnosis, 492 (1.86%) developed subsequent primary cancers. The most common type of secondary cancer was skin and mucosa (n=131, 26.63%) followed b... Both patients and physicians should be taught about the importance of prevention and the provision of care and screening services among cancer survivors. Studying the epidemiology, susceptibility, and...